EXTRIP工作组关于巴氯芬中毒体外治疗的建议
EXTRIP工作组系统综述43项研究(1项比较队列、1项汇总结果队列、1项药代动力学建模、40例病例报告或系列),制定巴氯芬中毒体外治疗建议。巴氯芬在肾功能正常者中经间歇性血液透析为「中度可透析」(证据质量C),肾功能不全者为「可透析」(证据质量C)。急性巴氯芬中毒患者未发现体外治疗获益;肾功能不全者治疗剂量巴氯芬中毒的间接证据提示体外治疗可能缩短中毒性脑病持续时间。工作组建议急性巴氯芬中毒不在标准治疗外行体外治疗,肾功能不全者治疗剂量巴氯芬中毒建议行体外治疗,尤其昏迷需机械通气者。
要点
- EXTRIP工作组建议(弱推荐):急性巴氯芬中毒患者不在标准治疗外行体外治疗。
- EXTRIP工作组建议(弱推荐):肾功能不全者治疗剂量巴氯芬中毒行体外治疗,尤其昏迷需机械通气者。
- 巴氯芬经间歇性血液透析的可透析性:肾功能正常者为「中度可透析」(证据质量C),肾功能不全者为「可透析」(证据质量C)。
- 急性巴氯芬中毒25例、肾功能不全治疗剂量巴氯芬中毒46例的临床数据中未报告死亡或后遗症,历史对照死亡率罕见。
- 体外治疗的潜在获益需与置管、操作本身及巴氯芬撤药风险带来的额外花费和伤害相权衡。
适用人群与场景
- 急性巴氯芬中毒(故意自服过量)患者。
- 肾功能不全时治疗剂量巴氯芬蓄积中毒的患者。
处置流程与药物剂量
- 标准治疗包括停用巴氯芬、呼吸支持和癫痫发作治疗。
- 急性巴氯芬中毒:EXTRIP工作组建议不在标准治疗外行体外治疗(弱推荐)。
- 肾功能不全者治疗剂量巴氯芬中毒:EXTRIP工作组建议行体外治疗(弱推荐),尤其昏迷需机械通气者。
红旗征与不能漏的情况
- 昏迷需机械通气的肾功能不全治疗剂量巴氯芬中毒患者,按建议可行体外治疗。
研究设计与关键结果
- EXTRIP工作组系统综述43项研究(1项比较队列、1项汇总结果队列、1项药代动力学建模、40项患者报告或系列),制定巴氯芬中毒体外治疗建议。
- 巴氯芬可透析性:肾功能正常者经间歇性血液透析为「中度可透析」(证据质量C),肾功能不全者为「可透析」(证据质量C)。
- 临床数据包括急性巴氯芬中毒25例和肾功能不全治疗剂量巴氯芬中毒46例,未报告死亡或后遗症;历史对照死亡率罕见。
- 急性巴氯芬中毒患者未发现体外治疗获益;间接证据提示体外治疗可能缩短肾功能不全者治疗剂量巴氯芬中毒的中毒性脑病持续时间。
证据类型、等级与局限
- 证据类型:EXTRIP工作组系统综述与建议(43项研究:1项比较队列、1项汇总结果队列、1项药代动力学建模、40项患者报告或系列)。
- 可透析性证据质量:肾功能正常者「中度可透析」为C级,肾功能不全者「可透析」为C级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急性巴氯芬中毒:按EXTRIP工作组建议(弱推荐),不在标准治疗外行体外治疗。
- 肾功能不全者治疗剂量巴氯芬中毒:按EXTRIP工作组建议(弱推荐),行体外治疗,尤其昏迷需机械通气者。
- 决策时需权衡体外治疗的潜在获益与置管、操作本身及巴氯芬撤药风险相关的额外花费和伤害。
指南或共识出处
- EXTRIP工作组建议,发表于Kidney Int。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Baclofen toxicity results from intentional self-poisoning (acute baclofen poisoning) or accumulation of therapeutic dose in the setting of impaired kidney function. Standard care includes baclofen discontinuation, respiratory support and seizure treatment. Use of extracorporeal treatments (ECTRs) is controversial. To clarify this, a comprehensive review of the literature on the effect of ECTRs in baclofen toxicity was performed and recommendations following EXTRIP methods were formulated based on 43 studies (1 comparative cohort, 1 aggregate results cohort, 1 pharmacokinetic modeling, and 40 patient reports or series). Toxicokinetic data were available for 20 patients. Baclofen's dialyzability is limited by a high endogenous clearance and a short half-life in patients with normal kidney function. The workgroup assessed baclofen as "Moderately dialyzable" by intermittent hemodialysis for patients with normal kidney function (quality of evidence C) and "Dialyzable" for patients with impaired kidney function (quality of evidence C). Clinical data were available for 25 patients with acute baclofen poisoning and 46 patients with toxicity from therapeutic baclofen in kidney impairment. No deaths or sequelae were reported. Mortality in historical controls was rare. No benefit of ECTR was identified in patients with acute baclofen poisoning. Indirect evidence suggests a benefit of ECTR in reducing the duration of toxic encephalopathy from therapeutic baclofen in kidney impairment. These potential benefits were balanced against added costs and harms related to the insertion of a catheter, the procedure itself, and the potential of baclofen withdrawal. Thus, the EXTRIP workgroup suggests against performing ECTR in addition to standard care for acute baclofen poisoning and suggests performing ECTR in toxicity from therapeutic baclofen in kidney impairment, especially in the presence of coma requiring mechanical ventilation.
参考来源
- Ghannoum M, Berling I, Lavergne V, et al. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning. Kidney Int. 2021. PMID: 34358487. doi:10.1016/j.kint.2021.07.014
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。